- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
2021 Managed Healthcare Executive® Pharmacy Survey: Lasting Effects of the Pandemic
In this part two series, participants give their opinions on the lasting effects of the pandemic. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next several days.
The pandemic flipped the switch on telehealth and at-home care, and the respondents to our annual Pharmacy Survey see them as having staying power. A quarter of the respondents said the increased use of telehealth will be the most important, lasting effect of the pandemic on the U.S. healthcare system and 35% put at-home care of all kinds in that category. Although many experts see the pandemic as accelerating the adoption of value-based payment, only 4% of our respondents ranked that as the pandemic’s most important lasting effect.
Not surprisingly, an increase in research and development on infectious disease got the most votes for the important, lasting effect on the pharmaceutical sector.
The online survey was conducted from April 5 through May 10.
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
